These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2998532)

  • 1. Use of the discriminant index in dynamic treatment to reduce recurrence of calcium oxalate kidney stones.
    Perlberg S; Azoury R; Garti N; Sarig S
    Br J Urol; 1985 Oct; 57(5):500-4. PubMed ID: 2998532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change in inhibitory potential in urine of hyperuricosuric calcium oxalate stone formers effected by allopurinol and orthophosphates.
    Goldwasser B; Sarig S; Azoury R; Wax Y; Hirsch D; Perlberg S; Many M
    J Urol; 1984 Nov; 132(5):1008-11. PubMed ID: 6492268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allopurinol treatment of renal calcium stone disease.
    Fellström B; Backman U; Danielson BG; Holmgren K; Johansson G; Lindsjö M; Ljunghall S; Wikström B
    Br J Urol; 1985 Aug; 57(4):375-9. PubMed ID: 4027505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers.
    Favus MJ; Coe FL
    Scand J Urol Nephrol Suppl; 1980; 53():265-71. PubMed ID: 6938003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of allopurinol treatment on the prevention of hyperuricosuric calcium oxalate lithiasis.
    Hofbauer J; Zechner O
    Eur Urol; 1988; 15(3-4):227-9. PubMed ID: 3215256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of hyperoxaluria in idiopathic calcium oxalate kidney stone disease.
    Baggio B; Gambaro G; Favaro S; Borsatti A
    Nephron; 1983; 35(1):11-4. PubMed ID: 6888620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of allopurinol in the prevention of calcium oxalate calculi.
    Ettinger B; Tang A; Citron JT; Livermore B; Williams T
    N Engl J Med; 1986 Nov; 315(22):1386-9. PubMed ID: 3534570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allopurinol in the prevention of calcium oxalate renal stones. Preliminary results.
    Miano L; Petta S; Gallucci M
    Eur Urol; 1979; 5(4):229-32. PubMed ID: 436867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine composition in patients with renal stone disease during treatment with allopurinol.
    Tiselius HG; Larsson L
    Scand J Urol Nephrol; 1980; 14(1):65-71. PubMed ID: 7375845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder.
    Coe FL
    Ann Intern Med; 1977 Oct; 87(4):404-10. PubMed ID: 907239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of oxalate and calcium oxalate activity and formation product ratio in patients with renal stones before and during treatment.
    Peña JC; Monforte MF; Briceño A
    J Urol; 1987 Nov; 138(5):1137-40. PubMed ID: 3669156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formation of a single calcium stone of renal origin. Clinical and laboratory characteristics of patients.
    Strauss AL; Coe FL; Parks JH
    Arch Intern Med; 1982 Mar; 142(3):504-7. PubMed ID: 7065787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium-uric acid nephrolithiasis.
    Coe FL
    Arch Intern Med; 1978 Jul; 138(7):1090-3. PubMed ID: 666467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of the urinary potential of hyperuricosuric patients to retard calcium oxalate precipitation.
    Goldwasser B; Sarig S; Azoury R; Orda S; Boichis H; Wax Y; Many M
    Eur Urol; 1985; 11(1):40-3. PubMed ID: 3987747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-Term Changes in Urinary Relative Supersaturation Predict Recurrence of Kidney Stones: A Tool to Guide Preventive Measures in Urolithiasis.
    Ferraro PM; Ticinesi A; Meschi T; Rodgers A; Di Maio F; Fulignati P; Borghi L; Gambaro G
    J Urol; 2018 Nov; 200(5):1082-1087. PubMed ID: 29940247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age, Body Mass Index, and Gender Predict 24-Hour Urine Parameters in Recurrent Idiopathic Calcium Oxalate Stone Formers.
    Otto BJ; Bozorgmehri S; Kuo J; Canales M; Bird VG; Canales B
    J Endourol; 2017 Dec; 31(12):1335-1341. PubMed ID: 29084490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preventive medical treatment of recurrent urinary calcium calculi].
    François B; Trolliet P; Cahen R; Semet MP
    Nephrologie; 1986; 7(1):9-12. PubMed ID: 3960261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up of drug therapy efficacy to prevent recurrence of calcium oxalate kidney stone formation.
    Sarig S; Garti N; Azoury R; Perlberg S; Wax Y
    J Urol; 1983 Jun; 129(6):1258-61. PubMed ID: 6854813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations.
    Cheungpasitporn W; Erickson SB; Rule AD; Enders F; Lieske JC
    J Urol; 2016 May; 195(5):1476-1481. PubMed ID: 26598423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.